# Unnatural Products

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unnatural-products

- Industry: Biotechnology
- Headquarters: Santa Cruz, US
- Website: www.unnaturalproducts.com
- Total disclosed funding: $68M
- Latest round: Series B (Mar 16, 2026)
- Investors on record: 17

## About

Unnatural Products Inc. is a biotechnology company based in the US, specializing in the development of synthetic macrocycles to address complex drug targets that conventional therapies often fail to reach. Founded in 2017 by Joshua Schwochert and currently led by CEO Cameron Pye, Unnatural Products Inc. is headquartered in Santa Cruz, California. Unnatural Products (UNP) provides synthetic macrocycles designed to tackle complex drug targets that are traditionally challenging for small molecules and biologics. Leveraging an AI-enhanced discovery platform, UNP's macrocycles mimic natural compounds to facilitate oral administration and effective engagement with biological targets. The primary clientele comprises pharmaceutical companies and research institutions in North America and Europe, addressing significant unmet needs in drug development. Unnatural Products generates revenue primarily through partnerships and B2B transactions with pharmaceutical firms and research organizations. The revenue model includes licensing agreements, milestone payments, and royalties tied to successful commercialization of its synthetic macrocycle therapeutics. Although specific pricing details are not disclosed, the structure typically involves upfront fees complemented by performance-based royalties, aligning the company’s interests with those of its partners.

## Funding rounds

- Series B, Mar 16, 2026, $45M — Merck Global Health Innovation Fund, ARTIS Ventures, argenx SE, Droia Ventures, The Venture Collective, First Spark Ventures
- Series A, Jul 14, 2023, $17M — Asset Management Ventures, Merck Global Health Innovation Fund, ARTIS Ventures, Better Ventures, Rising Tide, Wing, Gaingels, Abstract Ventures, Blue Bear Ventures, LongeVC, The Venture Collective, Not Boring Capital, First Spark Ventures, Humain, Modi Ventures
- Seed, Jul 1, 2018, $6M — Asset Management Ventures, ARTIS Ventures, Better Ventures, Rising Tide, Abstract Ventures, Blue Bear Ventures

## Investors

- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Seed, Series A
- ARTIS Ventures (https://capitalatlas.ai/funds/artis-ventures) — Seed, Series A, Series B
- Better Ventures — Seed, Series A
- Rising Tide — Seed, Series A
- Abstract Ventures (https://capitalatlas.ai/funds/abstract-ventures) — Seed, Series A
- Blue Bear Ventures (https://capitalatlas.ai/funds/blue-bear-ventures) — Seed, Series A
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series A, Series B
- Wing (https://capitalatlas.ai/funds/wing) — Series A
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Series A
- LongeVC (https://capitalatlas.ai/funds/longevc) — Series A
- The Venture Collective (https://capitalatlas.ai/funds/the-venture-collective) — Series A, Series B
- Not Boring Capital (https://capitalatlas.ai/funds/not-boring-capital) — Series A
- First Spark Ventures (https://capitalatlas.ai/funds/first-spark-ventures) — Series A, Series B
- Humain — Series A
- Modi Ventures (https://capitalatlas.ai/funds/modi-ventures) — Series A
- argenx SE — Series B
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series B